No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 39.7x · 10Y median 199.0x · 19th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:37:55.526Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T14:37:55.526Z. Latest historical point 2023-03-24.
The latest delayed quote for Humacyte, Inc. (HUMA) stock was $0.50 as of Oct 6, 2026, 10:35 AM EDT, up 0.28% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -76.0% · 3-year avg -43.9%/yr · 5-year avg -45.7%/yr
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting.
Biotechnology · Durham, NC
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.09
Revenue Est.
$769380.00
Last Quarter Results
EPS
$-0.16
vs Estimate
$-0.10
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1HUMA | $84.24M | $0.50 | +0.28% | -76.03% | -45.73% | N/A | N/A |
| 2NTRB | $84.24M | $6.93 | -7.23% | -4.74% | +6.67% | N/A | vs HUMA |
| 3CGTX | $84.58M | $0.94 | +0.74% | -39.33% | N/A | N/A | vs HUMA |
| 4ATRA | $83.82M | $9.30 | -1.03% | -34.63% | -53.60% | -32.27% | vs HUMA |
| 5CNXU | $85.09M | $3.18 | +1.92% | N/A | N/A | N/A | vs HUMA |
| 6CTOR | $82.75M | $0.89 | +1.89% | -53.61% | N/A | N/A | vs HUMA |
N/A
$406000.00
vs Estimate
$1.04M
Consensus Rating
Based on 5 analysts
Average Price Target
$1.85
+269.0% upside
Low
$1.00
Current
$0.50
High
$4.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.10 | $-0.09 | $-0.08 | 3 |
| Quarter ending Dec 2026 | $-0.10 | $-0.09 | $-0.07 | 3 |
| Quarter ending Mar 2027 | $-0.14 | $-0.08 | $-0.02 | 1 |
| Quarter ending Jun 2027 | $-0.14 | $-0.08 | $-0.02 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.46 | $-0.40 | $-0.37 | 4 |
| FY 2027 | $-0.29 | $-0.24 | $-0.21 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $715702.00 | $769380.00 | $823057.00 | 3 |
| Quarter ending Dec 2026 | $965481.00 | $1.84M | $2.71M | 3 |
| Quarter ending Mar 2027 | $886124.00 | $1.93M | $3.14M | 1 |
| Quarter ending Jun 2027 | $1.29M | $2.80M | $4.57M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $2.52M | $3.51M | $4.50M | 4 |
| FY 2027 | $14.71M | $21.73M | $28.75M | 4 |
